Opiant Pharmaceuticals to Report First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 10, 2022
Get Alerts OPNT Hot Sheet
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 4.1%
EPS Growth %: -100.0%
Join SI Premium – FREE
SANTA MONICA, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, will report its financial results for the first quarter ended March 31, 2022, after the financial markets close on Tuesday, May 10, 2022.
The Company’s management team is scheduled to host a conference call and webcast with slides at 4:30 p.m. ET on Tuesday, May 10, 2022. To access the call, please dial 1-877-407-0792 in the U.S. or 1-201-689-8263 outside the U.S. and provide the conference ID number: 13728852. To access the live webcast, please visit https://viavid.webcasts.com/starthere.jsp?ei=1542632&tp_key=dabaa0a667. Following the live webcast, an archived version of the call will be available on the website.
Tuesday May 10 @ 4:30 pm ET
Domestic: | 1-877-407-0792 |
International: | 1-201-689-8263 |
Conference ID: | 13728852 |
Webcast: | https://viavid.webcasts.com/starthere.jsp?ei=1542632&tp_key=dabaa0a667 |
About Opiant Pharmaceuticals, Inc.
Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose.
For more information visit: www.opiant.com.
For Media and Investor Inquiries:
Ben Atkins, Opiant
(310) 598-5410
[email protected]
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- Goosehead Insurance, Inc. to Report First Quarter 2024 Results
- Bridger Aerospace Announces Closing of $9.8 Million Registered Direct Offering
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!